AAUM (Average Assets Under Management) of ₹9,023.03 Cr for Jul-Sep 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 74.0% | 74.0% | ● 0.0% |
| Healthcare Services | 21.1% | 20.3% | ▼ -0.8% |
| Retailing | 2.5% | 2.5% | ● +0.0% |
| Healthcare Equipment & Supplies | 0.4% | 0.5% | ▲ +0.1% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 74.0% | 75.0% | ▲ +1.0% |
| Healthcare Services | 20.3% | 21.8% | ▲ +1.6% |
| Retailing | 2.5% | 2.3% | ▼ -0.3% |
| Healthcare Equipment & Supplies | 0.5% | 0.5% | ● 0.0% |
Comparing Sep 2026 → Oct 2026
| # | Stock | Sector | Weight (Oct 2026) |
|---|---|---|---|
| 1 | Natco Pharma Limited ₹81.37 Cr |
Pharmaceuticals & Biotechnology | 0.90% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Fortis Healthcare Limited ₹204.04 Cr |
Healthcare Services | 1.13% | 2.25% | +1.12% |
| 2 | Dr. Reddy's Laboratories Limited ₹556.82 Cr |
Pharmaceuticals & Biotechnology | 5.45% | 6.13% | +0.68% |
| 3 | Max Healthcare Institute Limited ₹300.84 Cr |
Healthcare Services | 2.70% | 3.31% | +0.61% |
| 4 | Piramal Pharma Limited ₹237.41 Cr |
Pharmaceuticals & Biotechnology | 2.24% | 2.61% | +0.37% |
| 5 | Apollo Hospitals Enterprise Limited ₹463.62 Cr |
Healthcare Services | 4.89% | 5.10% | +0.21% |
| 6 | Cipla Limited ₹564.67 Cr |
Pharmaceuticals & Biotechnology | 6.01% | 6.21% | +0.20% |
| 7 | Gland Pharma Limited ₹247.84 Cr |
Pharmaceuticals & Biotechnology | 2.53% | 2.73% | +0.20% |
| 8 | Syngene International Limited ₹141.01 Cr |
Healthcare Services | 1.40% | 1.55% | +0.15% |
| 9 | Sai Life Sciences Limited ₹366.91 Cr |
Pharmaceuticals & Biotechnology | 3.92% | 4.04% | +0.12% |
| 10 | Anthem Biosciences Limited ₹117.69 Cr |
Pharmaceuticals & Biotechnology | 1.19% | 1.30% | +0.11% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Divi's Laboratories Limited ₹611.99 Cr |
Pharmaceuticals & Biotechnology | 7.10% | 6.73% | -0.37% |
| 2 | Thyrocare Technologies Limited ₹175.13 Cr |
Healthcare Services | 2.24% | 1.93% | -0.31% |
| 3 | GlaxoSmithKline Pharmaceuticals Limited ₹256.78 Cr |
Pharmaceuticals & Biotechnology | 3.11% | 2.83% | -0.28% |
| 4 | MedPlus Health Services Limited ₹205.59 Cr |
Retailing | 2.53% | 2.26% | -0.27% |
| 5 | Aurobindo Pharma Limited ₹128.93 Cr |
Pharmaceuticals & Biotechnology | 1.65% | 1.42% | -0.23% |
| 6 | Sun Pharmaceutical Industries Limited ₹1,049.97 Cr |
Pharmaceuticals & Biotechnology | 11.71% | 11.55% | -0.16% |
| 7 | Suraksha Diagnostic Ltd ₹123.26 Cr |
Healthcare Services | 1.51% | 1.36% | -0.15% |
| 8 | Akums Drugs and Pharmaceuticals Limited ₹98.90 Cr |
Pharmaceuticals & Biotechnology | 1.21% | 1.09% | -0.12% |
| 9 | Abbott India Limited ₹201.35 Cr |
Pharmaceuticals & Biotechnology | 2.32% | 2.22% | -0.10% |
| 10 | Indoco Remedies Ltd ₹34.40 Cr |
Pharmaceuticals & Biotechnology | 0.48% | 0.38% | -0.10% |
37 stocks — Oct 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹1,049.97 Cr |
Pharmaceuticals & Biotechnology |
11.55%
|
|
| 2 |
₹611.99 Cr |
Pharmaceuticals & Biotechnology |
6.73%
|
|
| 3 |
₹564.67 Cr |
Pharmaceuticals & Biotechnology |
6.21%
|
|
| 4 |
₹559.86 Cr |
Pharmaceuticals & Biotechnology |
6.16%
|
|
| 5 |
₹556.82 Cr |
Pharmaceuticals & Biotechnology |
6.13%
|
|
| 6 |
₹463.62 Cr |
Healthcare Services |
5.10%
|
|
| 7 |
₹399.74 Cr |
Pharmaceuticals & Biotechnology |
4.40%
|
|
| 8 |
₹366.91 Cr |
Pharmaceuticals & Biotechnology |
4.04%
|
|
| 9 |
₹320.68 Cr |
Pharmaceuticals & Biotechnology |
3.53%
|
|
| 10 |
₹300.84 Cr |
Healthcare Services |
3.31%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.